Fibrinogen-coated droplets of olive oil for delivery of docetaxel to a fibrin(ogen)-rich ascites form of a murine mammary tumor

Clinical Cancer Research

Volumn 10, Issue 20, 2004, Pages 7001-7010

  Einhaus, Charity M ^a   Retzinger, Andrew C ^a   Perrotta, Andre O ^a   Dentler, Michael D ^a   Jakate, Abhijeet S ^b   Desai, Pankaj B ^b   Retzinger, Gregory S ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DOCETAXEL; FIBRIN; FIBRINOGEN; HIRUDIN; OLIVE OIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; BREAST TUMOR; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG COATING; DRUG EFFECT; DRUG EFFICACY; DRUG RETENTION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASCITES; DRUG DELIVERY SYSTEMS; FEMALE; FIBRINOGEN; INFUSIONS, PARENTERAL; MAMMARY NEOPLASMS, ANIMAL; MICE; PLANT OILS; TAXOIDS;

EID: 6044238247     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0118     Document Type: Article

References (23)

1. Baier RE, Dutton RC. Initial events in interactions of blood with a foreign surface. J Biomed Mater Res 1969;3:191-206.
2. Retzinger GS, DeAnglis AP, Patuto SJ. Adsorption of fibrinogen to droplets of liquid hydrophobic phases: functionality of the bound protein and biological implications. Arterioscler Thromb Vasc Biol 1998;18:1948-57.
3. DeAnglis AP, Fox MD, Retzinger GS. Accumulation of fibrinogen-coated microparticles at a fibrin(ogen)-rich inflammatory site. Biotechnol Appl Biochem 1999;29:251-61.
4. O'Meara RAQ, Jackson RD. Cytological observations on carcinoma. Ir J Med Sci 1958;6:327-8.
5. Hiramoto R, Bernecky J, Jurandowski J, Pressman D. Fibrin in human tumors. Cancer Res 1960;20:592-3.
6. Jakate AS, Einhaus CM, DeAnglis AP, Retzinger GS, Desai PB. Preparation, characterization, and preliminary application of fibrinogen-coated olive oil droplets for the targeted delivery of docetaxel to solid malignancies. Cancer Res 2003;63:7314-20.
7. Nagy JA, Meyers MS, Masse EM, Herzberg KT, Dvorak HF. Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Res 1995;55:369-75.
8. Klein G. Comparative studies of mouse tumors with respect to their capacity for growth as "ascites tumors" and their average nucleic acid content per cell. Exp Cell Res 1951;2:518-73.
9. Friberg SJ. Comparison of an immunoresistant and an immunosusceptible ascites subline from murine tumor TA3. 1. Transplantability, morphology and some physicochemical characteristics. J Natl Cancer Inst (Bethesda) 1972;48:1463-76.
10. Fumoleau P, Chevallier B, Kerbrat P, et al. Current status of Taxotere (docetaxel) as a new treatment in breast cancer. Breast Cancer Res Treat 1995;33:39-46.
11. Nabholtz JM, Vannetzel JM, Llory JF, Bouffette P. Advances in the use of taxanes in the adjuvant therapy of breast cancer. Clin Breast Cancer 2003;4:187-92.
12. Retzinger GS, Meredith SC, Takayama K, Hunter RL, Kézdy FJ. The role of surface in the biological activities of trehalose 6,6′-dimycolate. Surface properties and development of a model system. J Biol Chem 1981;256:8208-16.
13. Bell JT. Polyoxyethylene sorbitan monopalmitate (Tween 40) as a vehicle for oil red O fat stain. Stain Tech 1959;34:219-21.
14. Retzinger GS, McGinnis MC. A turbidimetric method for measuring fibrin formation and fibrinolysis at solid - liquid interfaces. Anal Biochem 1990;186:169-78.
15. BERLEX Laboratories, Refludan prescribing information, 02-419-0069/October, 2002.
16. Retzinger GS, Meredith SC, Hunter RL, Takayama K, Kézdy FJ. Identification of the physiologically active state of the mycobacterial glycolipid trehalose 6,6′-dimycolate and the role of fibrinogen in the biologic activities of trehalose 6,6′-dimycolate monolayers. J Immunol 1982;129:735-44.
17. Hunter R, Strickland F, Kézdy F. The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile -lipophile balance J Immunol 1981;127:1244-50.
18. Tsakiris DA, Scudder L, Hodivala-Dilke K, Hynes RO, Coller BS. Hemostasis in the mouse (Mus musculus): a review. Thromb Haemost 1999;81:177-88.
19. Schwartz JD, Simantov R. Thrombosis and malignancy. In Vivo 1998;12:619-24.
20. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 1995;6:339-55.
21. Nannan Panday VR, Huizing MT, ten Bokkel Huinink WW, Vermorken JB, Beijnen JH. Hypersensitivity reactions to the taxanes paclitaxel and docetaxel. Clin Drug Investig 1997;14:418-27.
22. Whitlock PW, DeAnglis AP, Ackley KL, Clarson SJ, Retzinger GS. Distribution of silicon/e in tissues of mice of different fibrinogen genotypes following intraperitoneal administration of emulsified poly-(dimethylsiloxane). Exp Mol Pathol 2002;72:161-71.
23. DeAnglis AP, Retzinger GS. Fibrin(ogen) and inflammation: current understanding and new perspectives. Clin Immunol Newslet 1999;19:111-8.